Medicines for Malaria Venture

Partial resistance to artemisinin derivatives, the mainstay of malaria treatment, has been observed for two decades in South-East Asia, and more recently in Africa, creating an urgent need for new #innovations with novel mechanisms of action.  #AMR #WAAW 

Today at MMV, we’re marking World AMR Awareness Week (#WAAW) by going blue for #AMR as a reminder that the fight against #malaria is also a fight against antimalarial drug resistance.     Learn more about antimalarial drug resistance and how MMV and partners are tackling this threat to global health security: bit.ly/MMV_AMDR

MMV was formed as a product development partnership 25 years ago in response to parasite resistance to antimalarial medicines – the drugs were failing to treat the disease.    Together with our partners, we’ve come a long way in developing and delivering new antimalarials and saving more lives, but the fight against #malaria is still a race against resistance. Today, we continue innovating and developing new ways to stay one step ahead of the malaria parasite while progressing towards the global goal of zero malaria deaths. #WAAW #AMR RBM Partnership to End Malaria, Malaria No More, University of Tuebingen, Barcelona Institute for Global Health (ISGlobal), GRAS-BURKINA, Infectious Disease Research Collaboration, Clinical Research Unit of Nanoro (CRUN / URCN), National Institute for Medical Research (NIMR) - Tanzania, Tropical Diseases Research Centre (TDRC), Université de Kinshasa (UNIKIN), Amsterdam UMC, Liverpool School of Tropical Medicine, Malaria Research and Training Center/USTTB /Laboratory of Malarea Immunology and Vaccinology ., Kenya Medical Research Institute (KEMRI), London School of Hygiene and Tropical Medicine, U. of London, IVCC (Innovative Vector Control Consortium), PATH, FIND, Malaria Consortium, Jenner Institute, TDR, PMI Impact Malaria, Drug Discovery and Development Centre (H3D), University of Cape Town, Speak Up Africa, Roll Back Malaria, Impact Santé Afrique, Africa CDC, Pan American Health Organization, Malaysian Society of Parasitology and Tropical Medicine (MSPTM), Swiss Malaria Group, State Secretariat for Education, Research and Innovation SERI, United to Beat Malaria, Asia Pacific Leaders Malaria Alliance (APLMA), World Health Organization, MedAccess, GSK, Merck, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, PNG Institute of Medical Research 

According to the World Health Organization, antimicrobial resistance (#AMR) is one of the top threats to global health security.     AMR also threatens the efficacy of live-saving antimalarial drugs. To respond to this threat, we must do what it takes to extend the useful lifecycles of existing drugs and continue investing in new #innovations to stay one step ahead of resistance in the race to zero #malaria deaths. #WAAW    Learn more about antimalarial drug resistance: bit.ly/MMV_AMR 

The World Health Organization calls #climatechange the single biggest threat facing humanity, and this threat is greatest for the individuals, families and communities most at risk of #malaria and neglected tropical diseases. Our collective response will have a direct impact on saving people’s lives. #COP29 Drugs for Neglected Diseases initiative - DNDi, FIND, Kenya Medical Research Institute (KEMRI)

🎬 MMV is releasing a new video on antimalarial drug resistance this Thursday, to coincide with World AMR Awareness Week (#WAAW).     📢 Help us spread the word! WAAW is of critical importance to the global malaria community – achieving zero #malaria deaths and building a malaria-free future depends on our collective response to antimalarial drug resistance. 

An article providing a detailed overview of MMV’s Global Health Priority Box (GHPB) was recently featured on ACS Publications' Editors’ Choice list. Developed in partnership with the IVCC (Innovative Vector Control Consortium), the GHPB is an open-access collection of 240 compounds in various stages of drug discovery and development with confirmed activity against emerging pathogens and vectors.     The box – which is available free of charge – provides scientists with confirmed starting points to further advance the development of treatments and insecticides to tackle global health issues like drug resistance and communicable diseases.    Learn more about the GHPB and order yours before the end of the year: bit.ly/3ObjT5E

Research presented at this year’s annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) is reinforcing the need for urgent action to address antimalarial drug resistance. A study conducted in Uganda among children with complicated P. falciparum malaria has identified partial resistance to injectable artesunate.    Read the study in JAMA: bit.ly/3Od61YN 

The climate crisis is adding new layers of risk to global health security. Charting the way forward and protecting the most vulnerable from the impacts of #climatechange requires strong #partnerships, targeted #funding and #innovation in the ways we prevent and treat #malaria and other climate-sensitive diseases. #COP29 Drugs for Neglected Diseases initiative - DNDi, FIND, Kenya Medical Research Institute (KEMRI)

Today, the West African Network for Clinical Trials of Antimalarial drugs (WANECAM2) consortium announced positive results from KALUMI, a Phase 2 study of a novel, non-artemisinin #malaria drug combination in development with Novartis and MMV.     The results were presented during a symposium at the American Society for Tropical Medicine and Hygiene annual meeting, as you can see in the photos. The study showed ganaplacide-lumefantrine to be as equally efficacious as the current standard of care – artemether-lumefantrine – with both combinations found to be highly effective in treating young children with malaria.     This represents an important step forward in the fight against malaria, as partial resistance to artemisinin across Africa threatens progress.  #AMR #TropMed24   Learn more: bit.ly/4fKFi1k European & Developing Countries Clinical Trials Partnership (EDCTP) Deutsches Zentrum für Luft- und Raumfahrt e.V. (DLR) DLR-Standort Oberpfaffenhofen Faculté des Sciences et Techniques (FST)-USTTB, Mali Karolinska Institutet London School of Hygiene and Tropical Medicine, U. of London Université Claude Bernard Lyon 1 University of Tuebingen CERMEL-Université de Tours Université Abdou Moumouni (Niamey-Niger) Decision Modeling Center - AmsterdamUMC